Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesBlue Cross Blue Shield - NebraskaBCBS Nebraska intracameral implant Coverage Prior …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy M.58

    MA Intracameral Implants (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.58 alerts

    Get alerted when Policy M.58 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers one-time intracameral bimatoprost (Durysta) and travoprost (iDose TR) implants for reducing intraocular pressure in adults with open-angle glaucoma or ocular hypertension and specifies preauthorization requirements and clinical criteria for medical necessity.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Intracameral Implants (Preauthorization Required)
    Policy CodePolicy M.58
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMar 1, 2027
    Next Review DateFeb 3, 2027
    Key ActionObtain preauthorization and ensure all listed medical necessity criteria are met before administering an intracameral implant.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2specific intracameral products
    18+minimum patient age (years)
    10 mcgmax bimatoprost dose
    75 mcgmax travoprost dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Preauth
    administrative requirement

    Coverage Criteria

    Bimatoprost (Durysta) criteria

    One-time intracameral bimatoprost (Durysta) implant may be considered reasonable and necessary when ALL criteria below are met:

    ALL of the following

    • Patient is 18 years of age and older
    • Patient has tried and failed or is intolerant to at least one topical ophthalmic prostaglandin (e.g., bimatoprost, latanoprost, travoprost)
    • Patient has tried and failed or is intolerant or has a contraindication to at least one topical beta-adrenergic blocker (e.g., betaxolol, metipranolol, timolol)
    • Injection/implant will be administered only to the affected eye
    • Affected eye has not received prior treatment with bimatoprost (Durysta)
    • Dose does not exceed 10 mcg bimatoprost per affected eye

    Travoprost (iDose TR) criteria

    One-time intracameral travoprost (iDose TR) implant may be considered scientifically validated when ALL criteria below are met:

    ALL of the following

    • Patient is 18 years of age and older
    • Patient has tried and failed or is intolerant to at least one topical ophthalmic prostaglandin (e.g., bimatoprost, latanoprost, travoprost)
    • Patient has tried and failed or is intolerant or has a contraindication to at least one topical beta-adrenergic blocker (e.g., betaxolol, metipranolol, timolol)
    • Injection/implant will be administered only to the affected eye
    • Affected eye has not received prior treatment with travoprost (iDose TR)

    Not reasonable and necessary / Not covered

    Non-covered circumstances

    ALL of the following

    • Services that do not meet the above criteria are considered not reasonable and necessary
    • All other indications are considered not reasonable and necessary

    Procedure and Coding

    Relevant procedure and HCPCS codesmixed
    0660TImplantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach
    0661TRemoval and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant
    J7351Injection, bimatoprost intracameral implant, 1 microgram
    J7355Injection, travoprost intracameral implant, 1 microgram
    inv-05: Maximum bimatoprost dose per affected eye — 10 mcg.
    Maximum bimatoprost dose per affected eyeDose does not exceed 10 mcg bimatoprost per affected eye.
    Applies to productBimatoprost intracameral implant (Durysta).
    Related patient criterionAffected eye has not received prior treatment with bimatoprost (Durysta).
    inv-06: Maximum travoprost dose per affected eye — 75 mcg.
    Maximum travoprost dose per affected eyeDose does not exceed 75 mcg travoprost (iDose TR) per affected eye.
    Applies to productTravoprost intracameral implant (iDose TR).

    Provider Actions and Requirements

    Prior Authorization

    Preauthorization required; medical necessity criteria must be met

    Preauthorization is required for intracameral implants as indicated in the policy title; approval is contingent on meeting the listed medical necessity criteria for the specified product (bimatoprost Durysta or travoprost iDose TR). The criteria include: patient age ≥18, prior trial and failure or intolerance to at least one topical prostaglandin and at least one topical beta-adrenergic blocker (or contraindication), administration only to the affected eye, no prior treatment of the affected eye with the same intracameral product, and adherence to the product-specific dose limit (10 mcg bimatoprost per affected eye; 75 mcg travoprost per affected eye).

    • Patient is 18 years of age and older.
    • Tried and failed or intolerant to at least one topical ophthalmic prostaglandin (e.g., bimatoprost, latanoprost, travoprost).
    • Tried and failed or intolerant or contraindicated to at least one topical beta-adrenergic blocker (e.g., betaxolol, metipranolol, timolol).
    • Injection/implant administered only to the affected eye.
    • Affected eye has not received prior treatment with the same intracameral product (Durysta or iDose TR).
    • Dose does not exceed 10 mcg bimatoprost or 75 mcg travoprost per affected eye, as applicable.

    Definitions and Product Examples

    inv-09: Indication for intracameral implant — Open-angle glaucoma (OAG) / ocular hypertension (OHT) indication.
    IndicationReduction of intraocular pressure (IOP) in members with open-angle glaucoma (OAG) or ocular hypertension (OHT).
    Patient agePatient is 18 years of age and older.
    Use contextConsidered as an alternative for patients with poor adherence to topical therapy or ocular surface disease concerns.
    inv-10: Product examples — Durysta is a bimatoprost intracameral biodegradable implant; iDose TR is a travoprost intracameral implant.
    Bimatoprost product exampleDurysta — a bimatoprost intracameral biodegradable implant.
    Travoprost product exampleiDose TR — a travoprost intracameral implant.
    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Intracameral Implants (Preauthorization Required)
    Policy CodePolicy M.58
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewMar 1, 2027
    Next Review DateFeb 3, 2027
    Key ActionObtain preauthorization and ensure all listed medical necessity criteria are met before administering an intracameral implant.
    SourceLink
    On This Page
    Coverage CriteriaProcedure and CodingProvider Actions and RequirementsDefinitions and Product Examples
    Dose does not exceed 75 mcg travoprost (iDose TR) per affected eye
    Related patient criterion
    Affected eye has not received prior treatment with travoprost (iDose TR).
    Denial Risk

    High denial risk if criteria or indications are not met

    Services that do not meet the above specified criteria or other indications are considered not reasonable and necessary and therefore are likely to be denied.

    • If any of the product-specific criteria (age, prior therapies, laterality, prior same-drug exposure, dose limits) are not met, the service is not considered reasonable and necessary.
    • All other indications beyond those listed for Durysta and iDose TR are considered not reasonable and necessary.
    Therapeutic roleSustained‑release intracameral implants to provide prolonged IOP lowering and reduce dependence on topical drops.